Eric Gené will join the TCR Europe grid for a full-time programme in 2025 after being named as the second driver in the ...

Researchers sought to determine whether patients with T-ALL would be responsive to salvage therapy with homoharringtonine, cytarabine, and aclarubicin.

Immunocore has secured a piece of biotech industry history, becoming the first company to get an FDA approval for a cancer therapeutic based on T cell receptor (TCR) technology. The US regulator ...

TCR diversity is critical to fighting infections ... production of recombinant proteins with BioProtein Technologies and gene therapy programs at bluebird bio both in France and in the USA.

CTA approval marks Anocca’s transition to a clinical-stage company First-in-human VIDAR-1 trial begins with the deployment of ANOC-001 in Advanced Pancreatic Cancer at leading medical centres in ...